Exicure, Inc. (XCUR)
Oxford Ledge is still expanding full research coverage of XCUR. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
The company transitioned from a failed biotech developer to a shell acquiring GPCR Therapeutics USA to pursue clinical-stage cancer therapies while seeking acquisitions and partnerships.
SEC filings
- 8-K Departure/election of directors or officers 2026-06-30
- 8-K Regulation FD disclosure 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-29
- 8-K Departure/election of directors or officers 2026-04-10
- 8-K Other material event; Financial statements and exhibits 2026-04-02
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for XCUR. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open XCUR in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.